Literature DB >> 2964038

Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.

R D Horstmann1, H J Sievertsen, J Knobloch, V A Fischetti.   

Abstract

Isolated complement components were used to study the regulation of the alternative complement pathway C3 convertase (EC 3.4.21.47), also called C3b,Bb, on M protein-carrying (M+) and M protein-lacking (M-) streptococci. Neither M- nor M+ streptococci directly affected the formation or dissociation of the surface-bound C3b,Bb or the inactivation of surface-bound C3b by factor I. However, the activity of the serum control protein of the alternative complement pathway, factor H, in controlling streptococcus-bound C3b and C3b,Bb was 6-8 times stronger on M+ organisms than on M- organisms. Furthermore, M+ streptococci of different serotypes and purified streptococcal M6 protein were shown to selectively bind factor H, the dissociation constants ranging from 4.5 X 10(-6) M to 6 X 10(-7) M. We conclude that the antiphagocytic activity of streptococcal M protein may be due to complement inhibition mediated by the binding of factor H. Binding of a regulatory protein appears to be a previously unrecognized route by which a pathogen is able to evade alternative pathway activation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2964038      PMCID: PMC279833          DOI: 10.1073/pnas.85.5.1657

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Interaction between the third complement protein and cell surface macromolecules.

Authors:  S K Law; R P Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

2.  The C3-activator system: an alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

3.  Homologous regions within M protein genes in group A streptococci of different serotypes.

Authors:  J R Scott; S K Hollingshead; V A Fischetti
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

4.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

5.  Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

6.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

7.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

8.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

9.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  164 in total

1.  BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition.

Authors:  M G Barnes; A A Weiss
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes.

Authors:  B A Fernie-King; D J Seilly; C Willers; R Würzner; A Davies; P J Lachmann
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 3.  Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation.

Authors:  R D Horstmann
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

4.  Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

Authors:  Davide Serruto; Rino Rappuoli; Maria Scarselli; Piet Gros; Jos A G van Strijp
Journal:  Nat Rev Microbiol       Date:  2010-06       Impact factor: 60.633

5.  Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci.

Authors:  P P Cleary; J Peterson; C Chen; C Nelson
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

Review 6.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

7.  Characterization of group a streptococcal M23 protein and comparison of the M3 and M23 protein's ligand-binding domains.

Authors:  Kyongsu Hong
Journal:  Curr Microbiol       Date:  2007-09-04       Impact factor: 2.188

8.  Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding.

Authors:  Dan M Granoff; Serena Giuntini; Flor A Gowans; Eduardo Lujan; Kelsey Sharkey; Peter T Beernink
Journal:  JCI Insight       Date:  2016-09-08

9.  Resistance of Enterococcus faecium to neutrophil-mediated phagocytosis.

Authors:  R C Arduino; K Jacques-Palaz; B E Murray; R M Rakita
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

Review 10.  Surface Proteins on Gram-Positive Bacteria.

Authors:  Vincent A Fischetti
Journal:  Microbiol Spectr       Date:  2019-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.